The UC Brain Tumor Center, a center of excellence within the UC Gardner Neuroscience Institute and the UC Cancer Institute, is committed to the discovery of new treatments for brain tumors. That commitment embraces basic science research, translational research (the translation of laboratory discoveries into treatments) and clinical trials involving new drugs, treatments and technologies.
Basic & Translational Research
Our basic science and translational research team includes investigators, technicians, molecular epidemiologists and biostatisticians. Their laboratory efforts focus on cell interactions, development and regeneration. They also study how and why healthy cell processes go awry. Our Molecular Therapeutics Program develops front-line therapies for brain metastases as well as experimental therapies for recurrent tumors.
Brain Tumor Clinical Trials
Our clinical research team includes physicians in all neuroscience specialties, neuro-imaging specialists, research nurses and regulatory experts. Patients who seek treatment at our center will be offered the opportunity to participate in available clinical trials for which they qualify.
Several adult clinical trials are underway. Our clinical trials explore new therapies, treatments or procedures for several types of brain tumors and related conditions, including acoustic neuroma, gliomas, glioblastoma multiforme, metastatic brain tumors and radiation necrosis.
Molecular Therapeutics Program
The Molecular Therapeutics Program, believed to be the first translational, metastasis-specific program of its kind in the United States, is a collaboration between the UC Gardner Neuroscience Institute and the UC Cancer Institute. It will allow UC to build a subspecialized research team that will collaborate with the existing brain tumor clinicians and surgeons to address the problem of brain metastases through translational research and original clinical trials.